Alpha 2.0
Login Register
» Authors » Calum MacAulay

Calum MacAulay

Explore the profile of Calum MacAulay including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 144
Citations 2601
Followers 0
Related Specialties
Oncology
Ophthalmology
Biomedical Engineering
Top 10 Co-Authors
Michele Follen
Stephen Lam
Martial Guillaud
Wan L Lam
Pierre Lane
Rebecca Richards-Kortum
Anthony M D Lee
E Neely Atkinson
Bradley P Coe
Anais Malpica
Published In
J Biomed Opt
Gynecol Oncol
Biomed Opt Express
Opt Express
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Machine Learning and Computed Tomography Radiomics to Predict Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer: A Pilot Study
Janzen I, Ho C, Melosky B, Ye Q, Li J, Wang G, et al.
Cancers (Basel) . 2025 Jan; 17(1. PMID: 39796687
Background/objectives: Pembrolizumab monotherapy is approved in Canada for first-line treatment of advanced NSCLC with PD-L1 ≥ 50% and no EGFR/ALK aberrations. However, approximately 55% of these patients do not respond...
2.
Multimodal Optical Imaging of Ex Vivo Fallopian Tubes to Distinguish Early and Occult Tubo-Ovarian Cancers
Malone J, Tanskanen A, Hill C, Zuckermann Cynamon A, Hoang L, MacAulay C, et al.
Cancers (Basel) . 2024 Nov; 16(21). PMID: 39518057
There are currently no effective screening measures to detect early or occult tubo-ovarian cancers, resulting in late-stage detection and high mortality. This work explores whether an optical imaging catheter can...
3.
Imaging Biomarkers of Oral Dysplasia and Carcinoma Measured with In Vivo Endoscopic Optical Coherence Tomography
Malone J, Hill C, Tanskanen A, Liu K, Ng S, MacAulay C, et al.
Cancers (Basel) . 2024 Aug; 16(15). PMID: 39123478
Optical coherence tomography is a noninvasive imaging technique that provides three-dimensional visualization of subsurface tissue structures. OCT has been proposed and explored in the literature as a tool to assess...
4.
Three-Dimension Epithelial Segmentation in Optical Coherence Tomography of the Oral Cavity Using Deep Learning
Hill C, Malone J, Liu K, Ng S, MacAulay C, Poh C, et al.
Cancers (Basel) . 2024 Jun; 16(11). PMID: 38893263
This paper aims to simplify the application of optical coherence tomography (OCT) for the examination of subsurface morphology in the oral cavity and reduce barriers towards the adoption of OCT...
5.
Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response
Nagelberg A, Sihota T, Chuang Y, Shi R, Chow J, English J, et al.
Br J Cancer . 2024 Jun; 131(3):534-550. PMID: 38890444
Background: Identification of driver mutations and development of targeted therapies has considerably improved outcomes for lung cancer patients. However, significant limitations remain with the lack of identified drivers in a...
6.
Tensor radiomics: paradigm for systematic incorporation of multi-flavoured radiomics features
Rahmim A, Toosi A, Salmanpour M, Dubljevic N, Janzen I, Shiri I, et al.
Quant Imaging Med Surg . 2023 Dec; 13(12):7680-7694. PMID: 38106259
Background: Radiomics features hold significant value as quantitative imaging biomarkers for diagnosis, prognosis, and treatment response assessment. To generate radiomics features and ultimately develop signatures, various factors can be manipulated,...
7.
DNA Ploidy as a Potential Adjunct Prognostic Marker of Low-Risk Prostate Cancer Progression after Radical Prostatectomy
Pukl M, George M, Javanmardi A, Carraro A, Korbelik J, White R, et al.
Urol J . 2023 Jul; 21(2):80-86. PMID: 37481706
Purpose: Post prostatectomy PSA kinetics and General Grade Groups (GGG) are the strongest prognostic markers of biochemical recurrence (BCR) and prostate cancer (PCa)-specific mortality after radical prostatectomy. Despite having low-risk...
8.
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years
Silver A, Ho C, Ye Q, Zhang J, Janzen I, Li J, et al.
Curr Oncol . 2023 Jun; 30(6):5546-5559. PMID: 37366902
Health Canada approved pembrolizumab in the first-line setting for advanced non-small-cell lung cancer with PD-L1 ≥ 50% and no EGFR/ALK aberration. The keynote 024 trial showed 55% of such patients...
9.
Automated PD-L1 Scoring for Non-Small Cell Lung Carcinoma Using Open-Source Software
Naso J, Povshedna T, Wang G, Banyi N, MacAulay C, Ionescu D, et al.
Pathol Oncol Res . 2021 Jul; 27:609717. PMID: 34257575
PD-L1 expression in non-small cell lung cancer (NSCLC) is predictive of response to immunotherapy, but scoring of PD-L1 immunohistochemistry shows considerable interobserver variability. Automated methods may allow more consistent and...
10.
An improved algorithm using a Health Canada-approved DNA-image cytometry system for non-invasive screening of high-grade oral lesions
Parfenova E, Liu K, Harrison A, MacAulay C, Guillaud M, Poh C
J Oral Pathol Med . 2020 Dec; 50(5):502-509. PMID: 33275794
Background: DNA-image cytometry (DNA-ICM) is able to detect gross alterations of cellular DNA-content representing aneuploidy, a biomarker of malignancy. A Health Canada-approved DNA-ICM system, ClearCyte in combination with a cytopathologist's...